Skip to main navigation Skip to search Skip to main content

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

  • Lisa A Beck
  • , Diamant Thaçi
  • , Mette Deleuran
  • , Andrew Blauvelt
  • , Robert Bissonnette
  • , Marjolein de Bruin-Weller
  • , Michihiro Hide
  • , Lawrence Sher
  • , Iftikhar Hussain
  • , Zhen Chen
  • , Faisal A Khokhar
  • , Bethany Beazley
  • , Marcella Ruddy
  • , Naimish Patel
  • , Neil M H Graham
  • , Marius Ardeleanu
  • , Brad Shumel*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Abstract

Background: Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment. Objective: The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD. Methods: This ongoing, multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) assessed dupilumab treatment in adults previously enrolled in dupilumab trials. Patients received dupilumab 300 mg weekly up to 148 weeks. The primary outcome was safety. Results: Of 2677 patients enrolled and treated, 347 reached week 148. Mean self-reported drug compliance was 98.2%. Safety data were consistent with previously reported trials (270.1 adverse events [AEs]/100 patient-years; 6.9 serious AEs/100 patient-years) and the known dupilumab safety profile. Common AEs (≥ 5% of patients) included nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions. AD signs and symptoms showed sustained improvements during treatment with mean (standard deviation, mean percentage change from parent study baseline) Eczema Area and Severity Index 1.4 (3.2, − 95.4%) and weekly Pruritus Numerical Rating Scale 2.2 (1.8, − 65.4%) at week 148. Limitations: No control arm; fewer patients at later time points; regimen different from the approved 300 mg every 2 weeks dose. Conclusion: These safety and efficacy results support dupilumab as a continuous long-term treatment for adults with moderate-to-severe AD. Trial Registration: ClinicalTrials.gov: NCT01949311. Video abstract: [MediaObject not available: see fulltext.]

Original languageEnglish
Pages (from-to)567-577
Number of pages11
JournalAmerican Journal of Clinical Dermatology
Volume21
Issue number4
DOIs
Publication statusPublished - Aug 2020

Fingerprint

Dive into the research topics of 'Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this